Aarti Drugs Limited (BOM:524348)

Market Cap	34.21B
Revenue (ttm)	24.77B
Net Income (ttm)	1.99B
Shares Out	91.27M
EPS (ttm)	22.89
PE Ratio	16.38
Forward PE	15.08
Dividend	1.00 (0.27%)
Ex-Dividend Date	Feb 4, 2025

Volume	5,007
Average Volume	8,717
Open	370.00
Previous Close	375.20
Day's Range	367.55 - 376.70
52-Week Range	312.50 - 574.95
Beta	0.18
RSI	33.24
Earnings Date	Jan 23, 2026

About Aarti Drugs

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1984
• Employees: 1,284
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524348

Financial Performance

In 2024, Aarti Drugs's revenue was 23.87 billion, a decrease of -5.60% compared to the previous year's 25.29 billion. Earnings were 1.68 billion, a decrease of -1.90%.